Cypros Pharmaceutical Corp. appoints Virgil Thompson to its board of directors.CARLSBAD, Calif.--(BUSINESS WIRE)--Jan. 26, 1996--Cypros Pharmaceutical Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CYPR) Friday announced that Virgil Thompson, 56, has been elected to its board of directors, replacing Dr. Lewis Sarett who has retired from the board after three years of service. Thompson spent the majority of his career at Syntex Corp. where he rose to the position of president of Syntex Laboratories. At Syntex he was responsible for a $1.2 billion portfolio of products. His experience in product launch is evidenced by products such as TORADOL, TICLID, Synerel and Cytovene. Thompson is currently the chief executive officer of Cytel Corp. in San Diego. ``Cypros is now an operating company operating company A business that engages in transactions with outsiders. with a sales and marketing presence and Virgil's operating/marketing experience will be invaluable to us as we build this function,'' said Paul J. Marangos, chairman and chief executive officer. ``Virgil will also play an important role in the market positioning of our clinical development candidates as we make the transition from Phase II to Phase III clinical trials and more clearly define eventual product labeling. His extensive training and experience in regulatory strategy will be very important in this regard.'' Thompson joins other Cypros board members: Paul J. Marangos, Ph.D., chairman; Robert Vukovich, Ph.D.; Bernard Levine, M.D.; and Digby Barrios Barrios is a name of Hispanic origin. The name may refer to: Persons
Cypros Pharmaceutical develops and markets acute-care, hospital- based products. The company's pre-clinical and clinical development programs focus on cytoprotective drugs designed to reduce ischemia (low blood flow) induced tissue damage in acute care settings. The company has three pre-clinical research and two clinical research programs. Five Phase II trials are currently in progress, which include three for CPC-111 (coronary artery bypass grafting coronary artery bypass graft n. Abbr. CABG A surgical procedure in which a section of vein or other conduit is grafted between the aorta and a coronary artery below the region of an obstruction in that artery. surgery, congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. and sickle cell anemia sickle cell anemia n. A chronic, usually fatal inherited form of anemia marked by crescent-shaped red blood cells, occurring almost exclusively in Blacks, and characterized by fever, leg ulcers, jaundice, and episodic pain in the joints. crises), and two for CPC-211 (in stroke and head injury patients). The company also markets two intravenous agents (Inulin inulin /in·u·lin/ (in´ul-in) a starch occurring in the rhizome of certain plants, yielding fructose on hydrolysis, and used in tests of renal function. in·u·lin n. and Glofil) used to assess kidney function. CONTACT: Cypros Pharmaceutical Corp., Carlsbad David W. Nassif, 619/929-9500 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion